AstraZeneca hopes warmer storage needs for COVID-19 vaccine will be an advantage against mRNA competitors

AstraZeneca is the latest player to unveil early COVID-19 vaccine data, and results seem to show an efficacy gap between at least one of its vaccine regimens and those of its two mRNA-based peers. But while investors may be less than enthused with the data, the vaccine does sport a major advantage in logistics given its much warmer storage needs.